FDA orphan designation for zenocutuzumab‑zbco targets NRG1 fusion–positive advanced cholangiocarcinoma, a small molecular subset within an aggressive malignancy with <15% five-year survival. Orphan ...
Every year, millions of newborns undergo routine screening as a preventive strategy to detect inherited disorders before ...
Hello. This is Mark Kris, from Sloan Kettering, continuing my discussion about the increasing precision of lung cancer therapies and the need for additional testing beyond our routine next-generation ...
Lee Zeldin, the E.P.A. administrator, revived a plan created during the first Trump administration to end the testing of chemicals on mammals. By Lisa Friedman The Environmental Protection Agency will ...
Genetic testing on embryos is more sophisticated and accessible than ever—and it’s now being sold as a way to let parents pick their future baby’s best traits. Many Americans agree that it’s ...
Skopje, 9 January 2026 (MIA) — The molecular biology and genomics lab at the Faculty of Natural Sciences and Mathematics will begin performing state health insurance-covered gene panel testing (next ...
While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...
NATICK, Mass., Nov. 12, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation ...
Herasight is a genetic screening company that charges $50,000 to allow hopeful parents to analyze embryos for genetic information like lifespan, height and IQ in life. Jeff Bezos’ Ex-Wife Confirms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results